Effects of a novel Y5 antagonist in obese mice: Combination with food restriction or sibutramine

Obesity

Volumn 16, Issue 7, 2008, Pages 1510-1515

  Mashiko, Satoshi ^a   Ishihara, Akane ^a   Iwaasa, Hisashi ^a   Moriya, Ryuichi ^a   Kitazawa, Hidefumi ^a   Mitobe, Yuko ^a   Ito, Junko ^a   Gomori, Akira ^a   Matsushita, Hiroko ^a   Takahashi, Toshiyuki ^a   MacNeil, Douglas J ^b   Van Der Ploeg, Lex H T ^b   Fukami, Takehiro ^a   Kanatani, Akio ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; DRUG DERIVATIVE; INSULIN; LEPTIN; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; SIBUTRAMINE; SPIRONOLACTONE;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; C57BL MOUSE; CALORIC RESTRICTION; DIET THERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; EATING; GENETICS; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MOUSE; MOUSE MUTANT; MULTIMODALITY CANCER THERAPY; OBESITY; PATHOPHYSIOLOGY; TIME;

ADIPOSITY; ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BLOOD GLUCOSE; BODY WEIGHT; CALORIC RESTRICTION; COMBINED MODALITY THERAPY; CYCLOBUTANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EATING; INSULIN; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; RECEPTORS, NEUROPEPTIDE Y; SPIRONOLACTONE; TIME FACTORS;

MUS; RODENTIA;

EID: 46249086222     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.223     Document Type: Article

References (30)

1. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415.
2. Klein S. Long-term pharmacotherapy for obesity. Obes Res 2004;12(Suppl):163S-166S.
3. Halford JC. Pharmacotherapy for obesity. Appetite 2006;46:6-10.
4. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441-61, vii.
5. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;296:659-660.
6. Parker E, Van Heek M, Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 2002;440:173-187.
7. Gerald C, Walker MW, Criscione L et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 1996;382:168-171.
8. Mullins D, Kirby D, Hwa J et al. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol Pharmacol 2001;60:534-540.
9. Mashiko S, Ishihara A, Iwaasa H et al. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology 2003;144:1793-1801.
10. Henry M, Ghibaudi L, Gao J, Hwa JJ. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes Res. 2005;13:36-47.
11. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-654.
12. Ishihara A, Kanatani A, Mashiko S et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci USA 2006;103:7154-7158.
13. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998;4:718-721.
14. Criscione L, Rigollier P, Batzl-Hartmann C et al. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest 1998;102:2136-2145.
15. Daniels AJ, Grizzle MK, Wiard RP, Matthews JE, Heyer D. Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regul Pept 2002;106:47-54.
16. Turnbull AV, Ellershaw L, Masters DJ et al. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 2002;51:2441-2449.
17. Weinberg DH, Sirinathsinghji DJ, Tan CP et al. Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 1996;271:16435-16438.
18. Uetsuki T, Naito A, Nagata S, Kaziro Y. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. J Biol Chem 1989;264:5791-5798.
19. Kanatani A, Mashiko S, Murai N et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000;141:1011-1016.
20. Mashiko S, Ishihara A, Iwaasa H et al. A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure. Mol Pharmacol 2006;71:602-608.
21. Kirkham TC, Williams CM. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl) 2001;153:267-270.
22. Barrachina MD, Martinez V, Wang L, Wei JY, Tache Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci USA 1997;94:10455-10460.
23. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005;146:3748-3756.
24. Kaya A, Aydin N, Topsever P et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004;58:582-587.
25. Wadden TA, Berkowitz RI, Womble LG et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000;8:431-437.
26. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51:581-585.
27. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
28. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002;440:119-128.
29. Erondu N, Gantz I, Musser B et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006;4:275-282.
30. Erondu N, Addy C, Lu K et al. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring) 2007;15:2027-2042.